

# MYELOMA VIIIth trial

<b>Submission date</b> 25/10/2000	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 25/10/2000	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 27/09/2019	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Mark Drayson

**Contact details**  
Department of Immunology  
Medical School  
University of Birmingham  
Vincent Drive  
Birmingham  
United Kingdom  
B15 2TT  
-  
m.t.draysom@bham.ac.uk

## Additional identifiers

**Protocol serial number**  
G8003737 expired Oct 99

## Study information

**Scientific Title**  
MYELOMA VIIIth trial

**Acronym**

MYELOMA VIIIth trial

**Study objectives**

To compare, for survival, the induction of first plateau phase in previously untreated patients with multiple myeloma, the efficacy of the above two treatments

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration.

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Leukaemia

**Interventions**

All patients receive three courses of ABCM. They are then randomised to continue with ABCM or to change to oral weekly cyclophosphamide.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Cyclophosphamide and ABCM

**Primary outcome(s)**

1. Survival
2. Obtaining plateau (stable disease with no more than minimal symptoms)
3. Quality of life

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

01/11/2000

**Eligibility**

## **Key inclusion criteria**

1. Greater than 65 years old and less than 75 years old
2. Myeloma
3. No previous cytotoxic therapy
4. Neutrophil count greater than or equal to  $1.3 \times 10^9/l$
5. Platelet count greater than or equal to  $75 \times 10^9/L$
6. Able to tolerate 3 l of fluid per day
7. Apyrexial
8. Free from infection
9. Informed consent

## **Participant type(s)**

Patient

## **Healthy volunteers allowed**

No

## **Age group**

Senior

## **Sex**

Not Specified

## **Key exclusion criteria**

Patients with equivocal myelomatosis

## **Date of first enrolment**

01/11/1993

## **Date of final enrolment**

01/11/2000

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

**Department of Immunology**

Birmingham

United Kingdom

B15 2TT

## **Sponsor information**

**Organisation**

Medical Research Council (MRC) (UK)

**Funder(s)****Funder type**

Research council

**Funder Name**

Medical Research Council (MRC) (UK)

**Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

**Funding Body Type**

Government organisation

**Funding Body Subtype**

National government

**Location**

United Kingdom

**Results and Publications****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration